ORKA
Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$74.48
+3.55%0
Insider buys (3m)
50
Insider sells (3m)
-$21.3M
Net value (3m)
-17.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | M-Exempt | 3,500 | $6.84 |
| Oct 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 200 | $78 |
| Oct 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 700 | $77 |
| Oct 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 1,400 | $75 |
| Oct 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 1,847 | $75 |
| Oct 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 2,853 | $74 |
| Oct 13, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | M-Exempt | 8,541 | $13 |
| Oct 13, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 200 | $83 |
| Oct 13, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 1,958 | $82 |
| Oct 13, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 2,100 | $81 |
| Oct 13, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 5,741 | $80 |
| Oct 13, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | M-Exempt | 1,458 | $34 |
| Oct 2, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | Sale | 16,246 | $83 |
| Oct 2, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | Sale | 200 | $85 |
| Oct 2, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | Sale | 8,554 | $84 |
| Oct 2, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | M-Exempt | 25,000 | $7.80 |
| Sep 21, 2026 | Quinlan Paul T · officer: General Counsel | M-Exempt | 10,000 | $7.80 |
| Sep 21, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 2,667 | $95 |
| Sep 21, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 601 | $94 |
| Sep 21, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 3,832 | $93 |
| Sep 21, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 2,900 | $92 |
| Sep 21, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 533 | $96 |
| Sep 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 2,384 | $91 |
| Sep 15, 2026 | Sandler Laura Lee · officer: Chief Operating Officer | Sale | 906 | $96 |
| Sep 15, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 1,039 | $96 |
| Sep 15, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | Sale | 2,452 | $96 |
| Sep 15, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 560 | $96 |
| Sep 15, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 200 | $94 |
| Sep 15, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 2,208 | $93 |
| Sep 15, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 4,051 | $92 |
Institutional positioning
13F filings over the trailing two quarters
New 161Increased 160Reduced 79Sold out 29
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 9,057,645 | Aug 13, 2026 |
| FMR LLC | Increased | 7,431,403 | May 15, 2026 |
| BlackRock, Inc. | Increased | 4,990,181 | Aug 7, 2026 |
| VR ADVISER, LLC | Unchanged | 4,148,428 | May 15, 2026 |
| VR Adviser, LLC | Unchanged | 4,148,428 | Aug 14, 2026 |
| Fairmount Funds Management LLC | Unchanged | 3,705,262 | Aug 14, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 3,705,262 | May 15, 2026 |
| BLACKROCK, INC. | Reduced | 3,527,087 | May 13, 2026 |
| Capital World Investors | New Position | 3,401,639 | Aug 12, 2026 |
| RTW INVESTMENTS, LP | Increased | 3,139,030 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 2,673,090 | Sep 22, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 2,666,690 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,360,971 | Aug 13, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 2,320,316 | May 15, 2026 |
| Paradigm Biocapital Advisors LP | Reduced | 2,144,526 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 15, 2026